Evidence map›Paper›PMID 37475009›Full record

ArticleCardiovascular diabetology2023

Alterations in trimethylamine-N-oxide in response to Empagliflozin therapy: a secondary analysis of the EMMY trial.

Faisal Aziz, Norbert J Tripolt, Peter N Pferschy, Ewald Kolesnik, Harald Mangge, Pero Curcic, Markus Hermann, Andreas Meinitzer, Dirk von Lewinski, Harald Sourij and 1 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular diabetology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT03087773. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03087773 phase3completed

Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction

Ran2017Enrolled476Registered outcomes6Posted comparisons0ConditionsAcute Myocardial InfarctionArmsempagliflozin 10 mg, Placebo Oral Tablet
PMID 36036746PMID 31901799PMID 38287198PMID 37236318PMID 37407956PMID 37777743other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Gut microbes · 2026
    Review
  3. Observational
  4. Review
  5. Review
  6. Review
  7. Review
  8. Timing of SGLT2i initiation after acute myocardial infarction.Cardiovascular diabetology · 2023 · on this map
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Faisal AzizInterdisciplinary Metabolic Medicine Trials Unit, Graz, Austria.
Norbert J TripoltInterdisciplinary Metabolic Medicine Trials Unit, Graz, Austria.
Peter N PferschyInterdisciplinary Metabolic Medicine Trials Unit, Graz, Austria.
Ewald KolesnikDivision of Cardiology, Medical University of Graz, Graz, Austria.
Harald ManggeClinical Institute for Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria.
Pero CurcicClinical Institute for Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria.
Markus HermannClinical Institute for Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria.
Andreas MeinitzerClinical Institute for Medical and Chemical Laboratory Diagnostics, Medical University of Graz, Graz, Austria.
Dirk von LewinskiDivision of Cardiology, Medical University of Graz, Graz, Austria. dirk.von-lewinski@medunigraz.at.
Harald SourijInterdisciplinary Metabolic Medicine Trials Unit, Graz, Austria. ha.sourij@medunigraz.at.
EMMY Investigators
Medical University of Graz · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe relationship between sodium glucose co-transporter 2 inhibitors (SGLT2i) and trimethylamine N-oxide (TMAO) following acute myocardial infarction (AMI) is not yet explored.

methodsIn this secondary analysis of the EMMY trial (ClinicalTrials.gov registration: NCT03087773), changes in serum TMAO levels were investigated in response to 26-week Empagliflozin treatment following an AMI compared to the standard post-MI treatment. Additionally, the association of TMAO changes with clinical risk factors and cardiorenal biomarkers was assessed.

resultsThe mean age of patients (N = 367) was 57 ± 9 years, 82% were males, and 14% had type 2 diabetes. In the Empagliflozin group, the median TMAO value was 2.62 µmol/L (IQR: 1.81) at baseline, 3.74 µmol/L (2.81) at 6 weeks, and 4.20 µmol/L (3.14) at 26 weeks. In the placebo group, the median TMAO value was 2.90 µmol/L (2.17) at baseline, 3.23 µmol/L (1.90) at 6 weeks, and 3.35 µmol/L (2.50) at 26 weeks. The serum TMAO levels increased significantly from baseline to week 6 (coefficient: 0.233; 95% confidence interval 0.149-0.317, p < 0.001) and week 26 (0.320, 0.236-0.405, p < 0.001). The average increase in TMAO levels over time (p

conclusionsOur results are contrary to existing experimental studies that showed the positive impact of SGLT2i on TMAO precursors and cardiovascular events. Therefore, we recommend further research investigating the impact of SGLT2i therapy on acute and long-term changes in TMAO in cardiovascular cohorts.

Indexed as

Diabetes Mellitus, Type 2Myocardial InfarctionSodium-Glucose Transporter 2 InhibitorsAgedBenzhydryl CompoundsFemaleGlucosidesHumansMaleMethylaminesMiddle AgedOxidesBenzhydryl CompoundsempagliflozinGlucosidesMethylaminesOxidesSodium-Glucose Transporter 2 InhibitorstrimethylaminetrimethyloxamineClinical trialEmpagliflozinHeart failureMyocardial infarctionRCTTrimethylamine N-oxide

Identifiers

PMID37475009
PMCPMC10357596
OpenAlexW4384925559

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.